Pharmafile Logo
Pharmafocus logo
Advanced Search

Galderma launches clinical trials for nemolizumab in systemic sclerosis and chronic pruritus of unknown origin

June 27, 2025
Research and Development Dermatology, Galderma, chronic pruritus of unknown origin, clinical trials, dermatological conditions, dermatology, nemolizumab, systemic sclerosis

Galderma has announced the launch of two phase 2 clinical trials evaluating its monoclonal antibody, nemolizumab, in two conditions: systemic …

News

STENTiT treats first patient with regenerative stent for limb preservation

June 27, 2025
Research and Development Cardiology, Medical University of Graz, STENTiT, chronic limb-threatening ischemia, clinical trial, limb amputation, peripheral artery disease, regenerative stent, resorbable fibrillated scaffold

STENTiT has announced the successful first patient implantation of its resorbable fibrillated scaffold (RFS), a new regenerative stent, as part …

News

Inizio Evoke appoints Kelly Cusumano to drive strategic growth and innovation

June 27, 2025
Business Services, Marketing Consultancies, Medical Communications Corporate, Evoke Comms, Inizio Evoke, business strategist, executive vice president, marketing and communications

Inizio Evoke, a global health marketing and communications platform, has appointed Kelly Cusumano as executive vice president, growth and client …

Appointment

Lexeo Therapeutics, PXV Funds and venBio launch new entity to advance RNA therapies for cardiac diseases

June 27, 2025
Mergers and Acquisitions, Research and Development Cardiology, Lexeo Therapeutics, PXV Funds, RNA-based therapies, cardiac genetic medicine, venBio Partners

Lexeo Therapeutics has announced a strategic partnership with life sciences investors Perceptive Xontogeny Venture Funds (PXV Funds) and venBio Partners …

News

Unlocking the gateway to ‘precision’ UK market access

June 27, 2025
Business Services, Market Access, Market Access Consultancy, Sales and Marketing NHS, Visions4Health

As the UK healthcare system navigates a period of significant change, the path to successful market access is becoming increasingly …

Feature
Thought Leadership

PMGroup/Visions4Health unveil Excellence in Healthcare Partnerships Awards

June 26, 2025
Medical Communications CHASE, Corporate, Excellence in Healthcare Partnerships Awards, NHS ConfedExpo, PMGroup, Visions4Health

PMGroup Worldwide and Visions4Health have launched the Excellence in Healthcare Partnerships (EHP) Awards to recognise collaborations that deliver measurable benefits …

News

CSL Behring’s therapy for hereditary angioedema receives positive assessment in Germany

June 26, 2025
Market Access, Market Research, Medical Communications, Research and Development, Sales and Marketing CSL Behring, Institute for Quality and Efficiency in Health Care, Rare Diseases, clinical trials, hereditary angioedema, market access

CSL Behring has announced a key milestone for its hereditary angioedema (HAE) therapy, garadacimab, following a positive benefit assessment by …

News
Photo of patient

FDA grants orphan drug designation to antibody-mediated rejection treatment

June 26, 2025
Research and Development FDA, Immunology, Orphan Drug Designation, Sanofi, antibody-mediated rejection, clinical trials, immunology, inflammation, organ transplantation

Sanofi has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to riliprubart for …

News
money_pills_2

Oxeltis secures €800,000 grant to advance antiviral candidate for emerging tropical viruses

June 26, 2025
Medical Communications, Research and Development Corporate, Defense Innovation Agency, National Research Agency, Oxeltis, RNA viruses, Virology, contract research organisation

Oxeltis, a French contract research organisation specialising in medicinal and organic chemistry, has announced that it will lead the BUNYANTIVIR …

News
blood_test

Roche candidate shows early promise for treating haemophilia A

June 25, 2025
Research and Development Chugai, Haematology, Roche, clinical trial, haemophilia a, prophylactic therapy

Roche has announced encouraging early results from its phase 1/2 trial of NXT007, an investigational bispecific antibody for haemophilia A. …

News
weight-2036971_960_720

Novo Nordisk’s therapy delivers significant weight loss in trial

June 25, 2025
Research and Development Novo Nordisk, Obesity, obesity, weight loss, weight-related medical conditions

Novo Nordisk has announced promising results from its phase 3 REDEFINE 1 trial, showing that investigational weight loss therapy, CagriSema, …

News

Opterion Health strengthens board with appointments of Rice Powell and Mark Hahn

June 25, 2025
Research and Development CEO, Nephrology, Opterion Health, board of directors, cfo, chronic kidney disease, dialysis solution

Swiss life sciences company Opterion Health has appointed two senior industry figures to its board of directors: Rice Powell, former …

Appointment

PLL Therapeutics appoints renowned ALS expert Philippe Corcia to scientific board

June 25, 2025
Research and Development ALS Reference Centre, National ALS Motor Neuron Study Group, Neurology, PLL Therapeutics, amyotrophic lateral sclerosis (ALS), scientific board

PLL Therapeutics has appointed leading amyotrophic lateral sclerosis (ALS) researcher Philippe Corcia to its scientific board, marking a strategic move …

Appointment

NHS ConfedExpo 2025: a platform for change in UK health and care

June 24, 2025
Medical Communications Accenture, AstraZeneca, Corporate, Excellence in healthcare Partnership (EHP) Awards, Manchester, NHS ConfedExpo, NHS Confederation, NHS England, Novartis UK, Visions4Health

This year’s NHS ConfedExpo took place on 11 to 12 June at Manchester Central, bringing together around 9,000 attendees. Among …

News

Sarclisa recommended for EU approval in newly diagnosed multiple myeloma

June 24, 2025
Research and Development Committee for Medicinal Products for Human USE, EU, European Commission, European Medicines Agency, German-speaking Myeloma Multicenter Group, Oncology, Sanofi, blood cancer, monoclonal antibody

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended Sanofi’s Sarclisa (isatuximab) for approval in …

News

Neurizon confirms positive results for prospective ALS treatment

June 23, 2025
Research and Development Neurizon Therapeutics, Neurology, amyotrophic lateral sclerosis, blood-brain barrier, clinical data, neurodegenerative diseases

Neurizon Therapeutics has announced new preclinical data confirming that NUZ-001 and its active metabolite, NUZ-001 Sulfone, effectively cross the blood-brain …

News
handshake_2

AOTI achieves broad market access in Germany for diabetic foot ulcer therapy

June 23, 2025
Market Access, Medical Communications, Sales and Marketing AOTI, Diabetes, European pharma market, German pharma market, Wound Healing, diabetic foot ulcers, market access, positive recommendation

AOTI, focused on solutions for severe and chronic wounds, has announced that its unique topical wound oxygen (TWO2) therapy has …

News
blood-1813410_960_720

Novo Nordisk presents promising findings for haemophilia treatment

June 23, 2025
Medical Communications, Research and Development Haematology, International Society on Thrombosis and Haemostasis Congres, Novo Nordisk, clinical trial data, haemophilia, market approval

Novo Nordisk has presented data indicating that a direct switch to Mim8 (denecimig) prophylaxis treatment from emicizumab without a need …

News
louis-reed-pwckf7l4-no-unsplash_5

Terumo BCT showcases new CAR-T workflow enabling faster cell expansion

June 20, 2025
Manufacturing and Production CAR-T cell manufacturing, Devices, EULV, Eureka Biotechnology, Terumo Blood and Cell Technologies, cell therapy, eureka, gene therapy

Terumo Blood and Cell Technologies (Terumo BCT) has unveiled a new automated workflow that consolidates three critical CAR-T manufacturing steps …

News

NICE recommends spevigo for rare and severe psoriasis flares

June 20, 2025
Medical Communications, Research and Development Dermatology, NHS, National Institute for Health and Care Excellence, generalised pustular psoriasis

The National Institute for Health and Care Excellence (NICE) has recommended Spevigo (spesolimab) for the treatment of generalised pustular psoriasis …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025